A century-old drug, a few dollars to make. The 2018 gap was $99-vs-$7; the 2023–24 cuts changed the story — conditionally. Four myths, honestly sorted.
Structured with AI assistance and strictly fact-checked by our editorial team against primary sources. How we work →
Figures from RAND's international price study, BMJ Global Health production-cost analysis, KFF coverage data, and federal law. Where a number is an estimate or still changing, we say so.
| Item | Figure | Context | Source |
|---|---|---|---|
| United States | ~$99/vial (2018 mfr price) | US insulin spending tripled from $8B to $22.3B (ADA, 2012–2022). In 2022 the US paid ~9.7× the average of 33 wealthy nations (RAND). After the 2023–24 cuts, list prices run $25–72/vial. | RAND (2018/2022 data) · ADA · Lilly |
| Other wealthy nations | a fraction — ~6× to 13× less | ~6× less in Canada, ~8× Japan, ~10× Britain, ~13× Australia — the SAME modern analog insulin, from the same makers. They negotiate one national price. | RAND international price study |
| Production cost | $48–$133/year | A peer-reviewed analysis estimated a full year's supply could be made — at a profit — for roughly $48–70 (human insulin) and under $133 (modern analogs). | BMJ Global Health (peer-reviewed) |
| The catch — the $35 cap | Medicare only | The 2023 federal cap covers Medicare. Over 1 in 4 insulin users on individual/small-group plans still paid above $35; the uninsured rely on voluntary manufacturer programs. | KFF · federal law (2023) |
We compare what insulin costs, not what anyone should take, switch, or import. Drug decisions belong with you and a licensed prescriber.
Starting January 2023, a federal law capped insulin at $35 a month for everyone on Medicare, with no deductible — and the three big makers then cut their own list prices by roughly 70–78% and extended $35 caps to many people with private insurance. Millions got real relief, and an honest comparison has to say so as loudly as it says what follows.
The federal cap covers Medicare only. More than one in four insulin users on individual and small-group plans were still paying above $35, the cap applies only to insulins a plan actually covers, and the uninsured rely on voluntary manufacturer programs. A study found about 1 in 6 insulin users had stretched or skipped doses to save money — a cost data point that explains why this price gap is a life-or-death topic in a way most of our comparisons aren't.
Personal importation of prescription drugs is sharply restricted under US law. And the famous ten-times gap is the gross list-price picture: net of the rebates manufacturers quietly hand back, the US still paid about 2.3 times what other wealthy nations pay. The gap is real at either number — but honest journalism quotes both.
In 2022 — the last full year before the big price cuts — the United States was paying nearly ten times what 33 other wealthy nations paid for insulin combined — about 9.7 times their average (RAND). US prices ran roughly 6× Canada's, 8× Japan's, 10× Britain's and more than 13× Australia's, for the same modern analog insulin from the same manufacturers.
No. Insulin is a roughly 100-year-old drug, and a peer-reviewed BMJ Global Health analysis estimated a full year's supply could be produced at a profit for about $48–70 for human insulin, and under $133 for modern analogs. The price reflects the pricing system, not the chemistry.
It changed a lot — for Medicare. Since January 2023, federal law caps insulin at $35 a month for Medicare beneficiaries, and the three big makers cut list prices by 70–78% and extended caps to many privately insured patients. But the federal cap covers only Medicare: more than 1 in 4 insulin users on individual and small-group plans were still paying above $35, and the uninsured rely on voluntary programs.
No — it's the same modern analog insulin from the same makers. The only structural difference is that those countries negotiate a single national price, which the US, until very recently, didn't.
Personally importing prescription drugs is sharply restricted under US law, so it's rarely the clean shortcut it sounds like. And the famous ten-times gap needs an honest asterisk: it's the gross list-price gap. Net of rebates and discounts, the US still paid about 2.3× other wealthy nations — real, but not the frozen 10× of the headlines.
A study found about 1 in 6 US insulin users had stretched or skipped doses to save money — presented here strictly as a cost data point, not guidance. Treatment decisions belong with a licensed prescriber.
Wellness Vision does not sell medication, book trips, or receive referrals of any kind. The data comes from the public sources cited above. This is a cost comparison, not medical advice — nothing here tells anyone to start, stop, switch, or import a medication.
📋 Or get the free Medical Travel Cost Checklist — no email →
View provenance manifest for this video →
You shouldn't have to go broke to feel whole.
